The present investigation was aimed at developing the stability indicating spectrophotometric methods for the determination of nelfinavir mesylate (NEM) in pharmaceutical dosage forms. The stability of NEM was tested in various dissolution media maintained at ambient temperature and 37 o C for 48 h. Stability studies of NEM in various media indicated that the drug was stable in 0.1M HCl and pH 7.8 phosphate buffer. The λmax were found 201.4 and 212.0 nm for 0.1M HCl and pH 7.8 phosphate buffers respectively with low coefficient of variation of < 5.11 %. The linearity of NEM was found in the range of 0.5 -60 µg/mL for 0.1M HCl and 0.5 -40 µg/mL for pH 7.8 phosphate buffer. The validated methods were applied to determine NEM concentration in formulations. In-vitro dissolution testing indicated that the NEM was stable and drug release was uniform from tablet dosage forms. The optimized media could be employed to study the dissolution profiles of NEM in bioequivalence studies.
INTRODUCTION
Dissolution testing is based on the fact that the drug enters into solution per unit time. In vitro dissolution test is a quality control parameter to check batch-to-batch consistency of drug release from a formulation. It plays a significant role to assess the possible in vivo bio availability based on in vitro in vivo correlation of drug products 1 . Development of dissolution medium is one of the critical factors to perform dissolution test for any drug. It is often sought-after to have a dissolution medium that is stable and selective based on the formulation used. Dissolution media were developed earlier to improve the solubility of lipophilic drugs such as nimodipine 2 , cefixime trihydrate 3 , rifampicin 4 and valdecoxib 5 in dissolution media. The US FDA's recent guidance has increased awareness among industries and scientists regarding dissolution testing [6] [7] [8] . The FDA has not only provided guidelines for dissolution tests for oral modified release dosage forms, but also pointed to the need for individualizing the methods on a case by case for the drug products. The generic forms of many drugs are being formulated as extended release products after the expiry of patents. The authorized USP pending monograph for nelfinavir mesylate tablets specifies 0.1N HCl as dissolution medium 9 . We have earlier reported stability indicating dissolution media of abacavir sulphate did anosine and lamivudine and proposed their application for extended release formulations [10] [11] [12] . Therefore there is a tremendous scope for pharmaceutical scientists to develop suitable dissolution testing media for bioequivalence studies of newly developed formulations. Nelfinavir mesylate is 2-[2-hydroxy-3-(3-hydroxy-2-methyl-benzoyl)amino-4-phenylsulfanylbutyl]-N-tert-butyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxamide ( Figure 1 ). Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral poly proteins resulting in the formation of immature noninfectious viral particles. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol poly protein, resulting in noninfectious, immature viral particles 13, 14 . Nelfinavir mesylate (NEM) was selected as drug in the present study because more varieties of generic formulations are coming up in the market both as conventional and extended release dosage forms. The present investigation is aimed at designing the stability indicating dissolution media for the determination of nelfinavir mesylate in pharmaceutical dosage forms such as conventional and extended release tablets in bioequivalence studies.
MATERIALS AND METHODS Materials
Pure nelfinavir mesylate (NEM) was obtained as gratis sample from Matrix Laboratories, Hyderabad, India. Potassium dihydrogen phosphate of AR grade and other chemicals of AR grade were purchased from E. Merck ® (India) Ltd., Mumbai, India. Water used was triple distilled grade and prepared by all glass distillation apparatus (quartz distillation unit, Borosil®). Three brands of nelfinavir mesylate 250 mg tablets, i.e., Neve (P), Nevimune (Q) and Neviretro (R) were purchased from local market.
Stability studies
Nine dissolution media were selected and prepared such as distilled water, 0.1M HCl, pH 1.2 KCl-HCl buffers and pH 5.8, 6.2, 6.6, 7.0, 7.4 and 7.8 phosphate buffers as per the standards of United States Pharmacopoeia 15 . The pH of the buffers was measured and adjusted using pH Analyzer (Elico®, Model No. LI612). Stock solutions of NEM were prepared by dissolving accurately weighed (Afcoset ® electronic balance) 25 mg of NEM in 2 mL of methanol and the volume was made up to 25 mL of distilled water, 0.1M HCl, pH 1.2 KCl-HCl buffer and pH 5.8, 6.2, 6.6, 7.0, 7.4 and 7.8 phosphate buffer separately to obtain 1 mg/mL solutions. All the solutions were sonicated using an ultrasonic bath (Enertech®) to dissolve the drug. From these solutions 2.5 mL was pipette out (Genie® micropipettes) into 25 mL volumetric flask and diluted with the same solvent system to obtain 100 µg/mL solutions. The stability of 100 µg/mL solutions of NEM was tested in the above prepared dissolution media at room temperature (RT, 25 ± 5 o C) and 37 ± 2 o C in an incubator (Thermolab®) for 48 h separately. Two sets of these solutions were prepared and maintained at RT and 37 o C in an incubator. All the samples were centrifuged (Remi ® ) for 5 minutes before scanning. The samples were scanned at 0, 24 and 48 h intervals using a double-beam UVvisible spectrophotometer (Elico ® , India, model SL 169) connected to computer loaded with Spectral Treats® software. The λ max and absorbance were measured to verify any deviations in the values. The above procedure was followed for all the media. The dissolution media that have shown stability of the drug were selected for further evaluation.
Development and validation of analytical methods
Standard graphs of NEM were constructed for the selected dissolution media after optimizing the conditions based on stability studies. Absorbance's were determined for NEM at selected λ max values using UV-visible spectrophotometer (Elico ® , India, model SL 169) for each of the above selected stable media after making dilutions to obtain 0.1 -100 µg/mL concentrations from the stock solutions. The beer's limit was determined from the constructed plots of wavelength vs absorbance. The proposed methods were validated for accuracy, precision and robustness. The methods were tested for intra-and inter-day variations. The recovery studies were carried out by adding known amounts of (10 µg and 20 µg) of NEM to the pre-analyzed samples and subjecting them to the proposed UV spectrophotometric methods. Replicates of six samples were tested in the above studies.
Assay of nelfinavir mesylate in commercial formulations
The estimation of NEM content in commercial formulations was carried out in the developed analytical methods using selected dissolution media. Contents of ten tablets containing NEM were pooled and powdered. The powder equivalent to 25 mg of NEM was extracted into selected medium and the volume was adjusted to 25 mL, mixed by sonication and filtered through a 0.45 µm Whatman filter paper. From the filtrate 0.1 mL was pipette into a 10 mL graduated test tube and then the volume was adjusted to 10 mL with the dissolution medium and was assayed for NEM content using selected methods. The above procedure was followed for remaining tablet brands and for all the selected methods in replicates of six.
In-vitro dissolution rate testing
The in-vitro test was conducted to verify the stability of NEM in the optimized and selected dissolution media during the dissolution testing. The dissolution testing was carried out in a six-stage dissolution rate testing apparatus USP XXI (Labindia, Mumbai, India). A 900 mL of the selected dissolution medium was taken separately and dissolution test was performed using the paddle method at 37 o c and 75 RPM. Aliquot volumes of 5 mL each were withdrawn from the dissolution bowl at various time intervals, i.e., 5, 10, 15, 20, 30, 35, 45 and 60 minutes. The samples were replaced by an equal volume of media and analyzed at selected λ max using UV-visible spectrophotometer (Elico ® , India, model SL 169) against blank solution containing dissolution medium after suitable dilution. The dissolution test was performed on the tablets of brand P employing the selected dissolution media.
RESULTS AND DISCUSSION
The stability of 100 µg/mL solutions of nelfinavir mesylate was successfully tested in nine dissolution media such as distilled water, 0.1M HCl, pH 1.2 KCl-HCl buffer and pH 5.8, 6.2, 6.6, 7.0, 7.4 and 7.8 phosphate buffers as per the standards of IP maintained at RT and 37 o C for 48 h separately. Stability studies of NEM in various media at RT and 37 o C indicated that the drug was stable in 0.1M HCl and pH 7.8 phosphate buffer in the UV region for a period of 48 h. The results are summarized in Table 1 and Figures 2 and 3. The λ max were found 201.4 and 212.0 nm for 0.1M HCl and pH 7.8 phosphate buffers respectively with an observed low coefficient of variation of < 5.11 %. The drug was unstable in other dissolution media and hence 0.1M HCl and pH 7.8 phosphate buffer were selected as dissolution media to estimate NEM in formulations. The analytical methods for NEM in the two selected dissolution media were developed and named as method A and B for 0.1M HCl and pH 7.8 phosphate buffers respectively. Standard graphs were constructed and linearity of the graphs were found in the range of 0.5 -60 µg/mL and 0.5 -40 µg/mL for 0.1M HCl and pH 7.8 phosphate buffer respectively. The regression equations from calibration graphs were found: y = 0.025x -0.001 (r 2 = 0.9993) and y = 0.001x + 0.0021 (r 2 = 0.9996) for media stated in the above order. The optical characteristics and regression analysis of proposed analytical methods in selected dissolution media are summarized in Table 2 . The methods were validated for precision, accuracy and robustness. A low coefficient of intra-and inter-day variation of 1.17-2.48% indicated that the two methods were highly precise (Table 3) . About 99.94, 99.98, 100.26 and 100.28 % of NEM could be recovered from the pre analyzed samples using these methods indicating that the proposed methods were accurate (Table 4) . Assay of three brands (P, Q and R) of NEM was determined using the developed methods. The mean amount of NEM determined to be 97.64 (102.15 %) and 99.87 (101.88 %) of the labeled amount for methods A and B respectively ( Table 5 ). The low percent of coefficient of variation (1.13 -2.46 %) indicated that the reproducibility of the assays of NEM in the tablet dosage forms. The commonly used excipients and additives in the pharmaceutical formulations did not interfere with the proposed methods. The in-vitro dissolution test was conducted to verify the stability of NEM in the optimized and selected dissolution media during the dissolution testing. The dissolution test was performed on the tablets of brand P employing the two dissolution media which were optimized. The results of in-vitro dissolution testing indicated that the drug was stable in simulated gastric fluid (0.1M HCl) and simulated intestinal fluid (pH 7.8 phosphate buffer) and drug release from the formulation was uniform (Figure 4) . The results showed that the optimized dissolution media could be employed to conduct dissolution testing of NEM tablets.
CONCLUSION
It was concluded that the two stable UV-spectrophotometric methods were developed and successfully applied as dissolution media to test in-vitro bioequivalence studies of nelfinavir mesylate. Analytical methods using optimized media were developed and they can be used for routine assay of NEM in various dosage forms. The developed dissolution media could be employed as simulated gastric fluid (0.1 M HCl) and simulated intestinal fluid (pH 7.8 phosphate buffer) to study the in-vitro dissolution profiles of tablets of NEM. Further these methods could be extended to bioequivalence studies of newly developed formulations of NEM in the selected liquid media for both conventional and extended release dosage forms.
